Open Access Open Access  Restricted Access Subscription or Fee Access

Nanotechnology Based Drug Delivery System in Tuberculosis: Review

Deeksha Sharma, Niharika Sinha, Rajesh Kumar Gupta, Anjana Sarkar

Abstract


From near the beginning centuries to present life Tuberculosis remains the world-wide disease without any limitations. In the other hand, in some cases in the infected individuals the disease remains in a dormant state. In this stage the treatment is hard as the lipid mycobacterial wall is thick & the delivery of drug inside the bacterial cell is difficult. Due to this new face of TB it becomes the major reason for high rates of mortality and morbidity. A newer nanotechnology based drug delivery system come within reach of to treat tuberculosis in improved method then the conventional treatment system as the drugs are difficult to process to patient because of poor termination, dissolution & low lipid permeability of drug hence they are not able to cross the lipid layer of bacterial cell. The main objective of the nanotechnology based treatment is to improve the patient complications and reduce the treatment time. Nanotechnology involves the curing with the various forms such as nanostructured lipid carrier, nanomolecules drug delivery system, nanoemulsions drug delivery system. These are characterized by droplet size analysis, drug content, viscosity determination, transmission electron microscopy (TEM), scanning electron microscopy (SEM), pH, zeta potential & release and in vitro skin permeation study. The present review articles detailed the new thought for the treatment of tuberculosis. The various nanostructured based drug delivery involves the advancement in the stematic delivery of biologically active agents for controlled drug targeting& delivery.

Full Text:

PDF

References


Meena LS .Survival mechanisms of pathogenic Mycobacterium tuberculosis H37Rv. FEBS J (2010)277:2416–27.

Zumla A, Raviglione M, Hafner R, von Reyn CF. Current concepts. N Engl J Med(2013) 368:745–55.

Jeong YJ, Lee KS. Pulmonary tuberculosis: up-to-date imaging and management. Am J Roentgenol (2008) 191:834–44.

S. H. Kaufmann, “Fact and fiction in tuberculosis vaccine research: 10 years later,” The Lancet Infectious Diseases,(2011) vol. 11, no. 8, pp. 633–640.

Sarkar S, Suresh MR. An overview of tuberculosis chemotherapy – a literature review. J Pharm Pharm Sci (2011) 14:148–6.

Singh J ,Garg T, Rath G, Goyal A .Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis – a critical review. Drug Delivery (2015) 23:5,1676-1698.

Gupta P, Garg T, Tanmay M, Arora S. Polymeric drug-delivery systems: role in P-gp efflux system inhibition. Crit Rev Ther Drug Carrier Syst (2015) 32:247-75.

Gupta RK, Thakur TS, Desiraju GR, Tyagi JS . Structure-Based Design of DevR Inhibitor Active against Nonreplicating Mycobacterium tuberculosis. J. Med. Chem. (2009),52:6324-6334.

Mitchison, D. A. Basic mechanisms of chemotherapy. Chest (1979), 76, 771–781.

Zhang Y, Yew W. Mechanisms of drug resistance in Mycobacterium tuberculosis. In: Chiang CY, ed. State of the art series. Drug-resistant tuberculosis. Number 1 in the series. Int J Tuberc Lung Dis (2009) 13:1320-30.

Kochi A, Vareldzis B, Styblo K. Multidrug-resistant tuberculosis and its control. Res Microbiol (1993) 144:104-10.

Wade MM, Zhang Y. Mechanisms of drug resistance in Mycobacterium tuberculosis. Front Biosci (2004) , 9:975-94.

Mikusova K, Slayden RA, Besra GS, Brennan PJ. Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrob Agents Chemother (1995) 39:2484-9.

Zhang Y, Wade MM, Scorpio A, et al. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother (2003),52:790-5.

Garg T, Rath G, Goyal AK. Colloidal drug delivery systems: current status and future directions. Crit Rev Ther Drug Carrier Syst (2015), 32:89–147.

Garg T, Rath G, Murthy RR, et al. Current nanotechnological approaches for an effective delivery of bioactive drug molecules to overcome drug resistance tuberculosis. Curr Pharm Des (2015), 21:3076-89.

Kaur G, Garg T, Rath G, Goyal AK. Archaeosomes: an excellent carrier for drug and cell delivery. Drug Deliv. (2015), doi:10.3109/10717544.2015.1019653.

Momoh M, Kenechukwu F, Attama A. Formulation and evaluation of novel solid-lipid microparticles as a sustained release system for the delivery of metformin hydrochloride. Drug Deliv (2013), 20:102-11.

Pandey R, Sharma S, Khuller G. Oral solid-lipid nanoparticlebased antitubercular chemotherapy. Tuberculosis (2005), 85:415–20.

Wang Y, Wu W. In situ evading of phagocytic uptake of stealth solid-lipid nanoparticles by mouse peritoneal macrophages. Drug Deliv (2006), 13:189–92.

Singh G, Pai RS. Pharmacokinetics and in vivo biodistribution of optimized PLGA nanoparticulate drug delivery system for controlled release of emtricitabine. Drug Deliv (2014), 21:627-35.

Banyal S, Malik P, Tuli HS, Mukherjee TK. (2013). Advances in nanotechnology for diagnosis and treatment of tuberculosis. Curr Opin Pulmon Med (2013), 19:289-97.

Parikh R, Patel L, Dalwadi S. Microparticles of rifampicin: comparison of pulmonary route with oral route for drug uptake by alveolar macrophages, phagocytosis activity and toxicity study in albino rats. Drug Deliv (2014), 21:406-11.

Sharma N, Mishra S, Sharma S, Deshpande RD, Sharma RK. reparation and Optimization of Nanoemulsions for targeting Drug Delivery Int. J. Drug Dev. & Res.,(2013),5(4): 37-48.

Thakur A, Walia MK, Kumar S. Nanoemulsion in enhancement of bioavailability of poorly soluble drugs: a review. Pharmacophore (2013), 4:15-25.

Bhatt P, Madhav S. (2011). A detailed review on nanoemulsion drug delivery system. Int J Pharm Sci Res (2011), 2:2292–8.

Setya S, Talegaonkar S, Razdan B. Nanoemulsions: formulation methods and stability aspects. World J Pharm Pharm Sci (2013), 3:2214-28.

Lifshitz IM, Slyozov VV. The kinetics of precipitation from supersaturated solid solutions. Journal of Physics and Chemistry of Solids (1961), 19:35–50.

Corswant CV, Thoren P, and Engstrom S. Triglyceride based microemulsion for intravenous administration of sparingly soluble substances. J Pharm Sci .(1998) 87:200–208 .

Nikonenko B, Reddy VM, Bogatcheva E, et al. Therapeutic efficacy of SQ641-NE against Mycobacterium tuberculosis. Antimicrob Agents Chemother(2014), 58:587–9.

Mushir A, Javed A Bali V. Study of surfactant combinations and development of a novel nanoemulsion for minimising variations in bioavailability of ezetimibe .Col. and Surf B: Biointerfaces (2010), 76:412.

Capek I. Degradation of kinetically-stable O/W emulsions . Review on mechanisms of destabilization of nano-emulsions. Adv in Colloid and Interf Sci (2004), 107:102-10.

Müller RH, Petersen RD, Hommos A, Pandeines RJ. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Reviews (2007), 59:22–30.

Del Pozo-R A, Delgado D, SolinísMA, GascónAR, Pedraz JL. Solid lipid nanoparticles: factors affecting cells transfection capacity. Int. J. of Pharm. (2007),339:261-8.

Teeranaichaideekul V, Souto EB, Junyaprasert VB, Müller RH. Cetyl palmitate-based NLC for topical delivery of coenzyme Q10: development, physicochemical characterization and in vitro release studies. Eur. J. of Pharm and Biopharm (2007), 67:141-8.

Koroleva MYu, Yurtov EV .Nanoemulsions: the properties, methods of preparation and promising Applications . Russian Academy of Sciences and Turpion Ltd (2012), 81:1.

Porras M, Martínez A, Solans C, González C, Gutierrez JM. Ceramic particles obtained using W/Onano-emulsions as reactionmedia.Colloids and Surfaces A, Physicochemical and Engineering Aspects (2005), 270-271:189-94.

Singh G, Dwivedi H, Saraf SK, Saraf SA. Niosomal delivery of isoniazid-development and characterization. Trop J Pharm Res (2011), 10:203-10.

El-Ridy MS, Yehia SA, Kassem MA-E-M, et al. Niosomal encapsulation of ethambutol hydrochloride for increasing its efficacy and safety. Drug Deliv (2015), 22:21-36.

Sharma R, Mahatma R, Bharkatiya M, Goyal A. Niosomes – as potential drug delivery system. Int J Drug Res Technol (2012), 2:422-9.

Gagandeep Garg T, Malik B, Rath G, Goyal AK. (2014). Development and characterization of nano-fiber patch for the treatment of glaucoma. Eur J Pharm Sci (2014), 53;10-16.

Li X, Guo Q, Zheng X, et al. Preparation of honokiol-loaded chitosan microparticles via spray-drying method intended for pulmonary delivery. Drug Deliv (2009), 16:160–6.

Kaur P, Garg T, Vaidya B, et al . Brain delivery of intranasal in situ gel of nanoparticulated polymeric carriers containing antidepressant drug: behavioral and biochemical assessment. J Drug Target (2014), 23: 275–86.

Parikh R, Patel L, Dalwadi S. Microparticles of rifampicin: comparison of pulmonary route with oral route for drug uptake by alveolar macrophages, phagocytosis activity and toxicity study in albino rats. Drug Deliv (2014), 21:406-11.

Saraogi GK, Sharma B, Joshi B, et al. Mannosylated gelatine nanoparticles bearing isoniazid for effective management of tuberculosis. J Drug Target (2011), 19:219–27.

Dubey R. Pure drug nanosuspensions-Impact of nanosuspension technology on drug discovery and development. Drug Del Tech (2006), 6:65-71.

Barret ER. Nanosuspensions in drug delivery. Nat Rev. (2004), 3:785–96.

Patel VR, Agrawal YK. Nanosuspension: An approach to enhance solubility of drugs. J Adv Pharm Technol Res (2011), 2(2):81-87.

Arunkumar N, Deecaraman N, Rani C. Nanosuspension technology and its application in drug delivery. Asian J. of pharm. (2009), DOI: 10.4103/0973-8398.56293.

Peters K, Leitzke S, Diederichs J, et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother (2000), 45:77-83.

Sharma R, Garg T, Goyal AK, Rath G. Development, optimization and evaluation of polymeric electrospun nanofiber: a tool for local delivery of fluconazole for management of vaginal candidiasis. Artif Cells Nanomed Biotechnol. [Epub ahead of print].(2014), doi:10.3109/21691401.2014.966194.

Veigas B, Doria G, Baptista PV. Nanodiagnostics for Tuberculosis, Understanding Tuberculosis Global Experiences and Innovative Approaches to the Diagnose, Dr. Pere-Joan Cardona (Ed.) ,(2012), ISBN: 978-953-307-938-7.

Chan, W.C.W., Maxwell, D.J., Gao, X., Bailey, R.E., Han, M., & Ni, S., Luminescent quantum dots for multiplexed biological detection and imaging, Current Opinion in Biotech (2002), 13,1:40-46.

Gazouli, M., Liandris, E., Andreadou, M., Sechi, L.A., Masala, S., Paccagnini, D., & Ikonomopoulos, J. Specific detection of unamplified Mycobacterial DNA by use of fluorescent semiconductor quantum dots and magnetic beads, J. of Clinical Micro (2010), 48, 8: 2830–2835.

Griffith, D.E., Aksamit, T., Brown-Elliott, B.A., Catanzaro, A., Daley, C., Gordin, F., Holland, S.M., Horsburgh, R., Huitt, G., Iademarco, M.F., Iseman, M., Olivier, K., Ruoss, S., von Reyn, C.F., Wallace, R.J., & Winthrop, K. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous Mycobacterial diseases, Amer J. of Resp and Critical Care Med. (2007), 175: 367416.

Yashodhara B, Huat CB, Naik LN, et al. Multidrug and extensively drug-resistant tuberculosis from a general practice perspective. Infect Drug Resist (2010), 3:115-22.

Goyal G, Garg T, Rath G, Goyal AK. Current nanotechnological strategies for an effective delivery of drugs in treatment of periodontal disease. Crit Rev Ther Drug Carrier Syst(2014), 31: 89–119.

Gupta RK, Thakur TS, Desiraju GR, Tyagi JS . Structure-Based Design of DevR Inhibitor Active against Nonreplicating Mycobacterium tuberculosis. J. Med. Chem. (2009),52:6324-6334.


Refbacks

  • There are currently no refbacks.